Genomics

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression

Thursday, July 9, 2020 - 10:40am

Rather than address genetic diseases by replacing, repairing or editing faulty genes, we set out to increase or stoke protein output from healthy genes.

Key Points: 
  • Rather than address genetic diseases by replacing, repairing or editing faulty genes, we set out to increase or stoke protein output from healthy genes.
  • These data show that we can increase full-length, fully functional protein expression from a variety of healthy genes, which supports our hypothesis and may lead to a new way of treating severe genetic diseases.
  • Stoke designed TANGO ASOs to target the non-productive splicing events in these genes and their activity was evaluated.
  • These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies.

First Extensive Validation Study of Saphyr for Constitutional Genetic Disorders by European Consortium Shows 100% Concordance to Standard Cytogenetics and Describes Resolution of Cases of Long-Standing, Undiagnosed Disease

Wednesday, July 8, 2020 - 11:14pm

Dr. El Khattabi expressed the consortiums confidence in Saphyrs potential to largely replace standard cytogenetic testing methods in the future.

Key Points: 
  • Dr. El Khattabi expressed the consortiums confidence in Saphyrs potential to largely replace standard cytogenetic testing methods in the future.
  • Dr. Alexander Hoischen from Radboud University Medical Center described how Bionano genome imaging identified likely pathogenic variants in 25% of unsolved rare disease cases analyzed with Saphyr.
  • Dr. Hoischen presented two of these research cases, which involved families with undiagnosed genetic disorders.
  • The study showed 100% concordance between Bionanos Saphyr system and standard cytogenetics in 48 leukemia patients.

WuXi NextCODE and Olink Proteomics announce strategic cooperation

Wednesday, July 8, 2020 - 11:58am

UPPSALA, Sweden and SHANGHAI, July 8, 2020 /PRNewswire/ -- WuXi NextCODE Genomics Co., Ltd. ("WuXi NextCODE") and Olink Proteomics AB today announced a strategic cooperation in China which gives WuXi NextCODE exclusivity as third-party provider of services using Olink products to customers in mainland China.

Key Points: 
  • UPPSALA, Sweden and SHANGHAI, July 8, 2020 /PRNewswire/ -- WuXi NextCODE Genomics Co., Ltd. ("WuXi NextCODE") and Olink Proteomics AB today announced a strategic cooperation in China which gives WuXi NextCODE exclusivity as third-party provider of services using Olink products to customers in mainland China.
  • It will also mean that WuXi NextCODE will further improve their capability for high-throughput multi-omics research, based on genomics, transcriptomics and proteomics.
  • Lele Sun, Ph.D. General Manager of WuXi NextCODE said, "We are pleased to become the strategic partner of Olink on the China market to promote Olink technology for detection of actionable protein biomarkers.
  • With that, WuXi NextCODE enters into a new era of providing multi-omics services to its customers, combining its genomics capability with Olink proteomics technology, to serve customers with comprehensive solutions for precision medicine."

Genome British Columbia: Supergenes play a larger role in evolution than previously thought

Wednesday, July 8, 2020 - 4:30pm

VANCOUVER, British Columbia, July 08, 2020 (GLOBE NEWSWIRE) -- Massive blocks of genesinherited together plug and play stylemay play a larger role in evolutionary adaption than previously thought, according to new research in Nature.

Key Points: 
  • VANCOUVER, British Columbia, July 08, 2020 (GLOBE NEWSWIRE) -- Massive blocks of genesinherited together plug and play stylemay play a larger role in evolutionary adaption than previously thought, according to new research in Nature.
  • What we found is that supergenes have a pervasive role in adaptation, and can be truly massive.
  • The largest of the supergenes identified in the study is comprised of more than 100 million base pairs (larger than many human chromosomes) and 1,819 genes.
  • Genome BC has been investing in this work since 2009, says Lisey Mascarenhas, Sector Director, Agrifood and Natural Resources at Genome BC.

Sema4 Introduces “Sema4 Signal™”, a New Family of Products and Services Delivering Data-driven Precision Oncology Solutions

Wednesday, July 8, 2020 - 1:00pm

Sema4 , a patient-centered health intelligence company, today announced the launch of Sema4 Signal, a new family of products and services providing data-driven precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.

Key Points: 
  • Sema4 , a patient-centered health intelligence company, today announced the launch of Sema4 Signal, a new family of products and services providing data-driven precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.
  • Sema4 Signal, our family of data-driven precision oncology care solutions, was designed to meet the needs of health systems, providers, patients, and payors, said Eric Schadt , PhD, Founder and Chief Executive Officer of Sema4.
  • Sema4 continues to scale up its previously launched Somatic solutions, including Sema4 Signal Whole Exome and Transcriptome Sequencing (WES and WTS) and Sema4 Signal PanCancer.
  • Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed at Advanced Cancer Immunotherapy

Monday, July 6, 2020 - 7:11am

The Division of Translational Oncoimmunology at the Aichi Cancer Center has been conducting translational research using patient samples in collaboration with the departments of Thoracic Surgery and Thoracic Oncology at the Aichi Cancer Center Hospital.

Key Points: 
  • The Division of Translational Oncoimmunology at the Aichi Cancer Center has been conducting translational research using patient samples in collaboration with the departments of Thoracic Surgery and Thoracic Oncology at the Aichi Cancer Center Hospital.
  • Aichi Cancer Center and NEC will identify neoantigens recognized by T cells by using both the neoantigen prediction system and the immunological experimental approach.
  • Aichi Cancer Center will aim to carry out clinical trials of cancer immunotherapy.
  • The clinical trials of cancer immunotherapy will be conducted at Aichi Cancer Center Hospital, and additional research will be conducted at Aichi Cancer Center Research Institute.

Worldwide Market Study for Whole Genome and Exome Sequencing to 2024 - Strategic Situation Analysis & COVID Impact

Wednesday, July 1, 2020 - 3:30pm

The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer-related activity has suffered.

Key Points: 
  • The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer-related activity has suffered.
  • Find out all about it in the comprehensive report of Whole Genome Sequencing.
  • The complete genome of the COVID virus is included as an example of the work being done.
  • The plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players.

Genome Medical Raises $14 Million to Expand Virtual Clinical Genetics Care and Accelerate Telemedicine Technology Development

Wednesday, July 1, 2020 - 1:25pm

The funds will specifically support the accelerated development of the Genome Care DeliveryTM technology platform to address the rapid growth in virtual care needs and the shortage of genomic health care experts.

Key Points: 
  • The funds will specifically support the accelerated development of the Genome Care DeliveryTM technology platform to address the rapid growth in virtual care needs and the shortage of genomic health care experts.
  • Existing investors, founders and additional growth partners also participated in this financing, bringing the total capital raised since Genome Medical was founded in 2016 to $60 million.
  • "We are pleased to partner with Samsung Catalyst Fund to forge consumer digital health technology together with genomic data and clinical genetics expertise to transform health care."
  • Genome Medical is a national telegenomics technology, services and strategy company bringing genomic medicine to everyday care.

Myriad Launches New GeneSight® Psychotropic Patient Collection Kit

Wednesday, July 1, 2020 - 12:05pm

SALT LAKE CITY, July 01, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the launch of a new patient home collection kit for the GeneSight Psychotropic test.

Key Points: 
  • SALT LAKE CITY, July 01, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the launch of a new patient home collection kit for the GeneSight Psychotropic test.
  • To accommodate this growing need for remote access and innovative solutions, we created this easy-to-use patient collection kit.
  • Clinicians who have determined that GeneSight is right for their patient may order the test through the secure, online GeneSight portal and request that the kit be sent directly to the patient.
  • To view a sample of the patient home collection kit, click here:
    The GeneSight Psychotropic test is the category-leading pharmacogenomic test for depression medications.

Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company - ResearchAndMarkets.com

Monday, June 29, 2020 - 5:37pm

The "Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company" report has been added to ResearchAndMarkets.com's offering.
  • The growth of the digital genome market is mainly attributed to factors such as the increasing prevalence of chronic diseases and growing funding for genomics.
  • However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.
  • Based on end user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others.